Document Detail

Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial.
MedLine Citation:
PMID:  22386829     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Hypertensive patients with diabetes often require combination therapy to achieve a blood pressure (BP) goal, and evidence suggests that time to BP goal is crucial to decrease cardiovascular risk.
OBJECTIVE: The aim of the study was to investigate whether the single-pill combination of telmisartan and amlodipine was superior to amlodipine alone as initial antihypertensive therapy in patients with diabetes and hypertension.
METHODS: An 8-week, randomized, parallel-group, double-blind international trial comparing the once-daily single-pill combination of telmisartan 80 mg and amlodipine 10 mg (T/A; n = 352) with once-daily amlodipine 10 mg (A; n = 354) in patients with type 2 diabetes mellitus and stage 1 or 2 hypertension (systolic BP [SBP] >150 mm Hg).
RESULTS: Patient demographics were similar between treatment groups, with an mean (SD) age of 60.5 (10.1) years; 51.7% were male, the mean (SD) body mass index was 32.0 (6.1) and the mean (SD) duration of hypertension was 8.8 (7.9) years. After 8 weeks (primary end point) as well as after 1, 2, and 4 weeks (key secondary end points), significantly greater decreases in the in-clinic mean seated trough cuff SBP with T/A versus A were achieved (-29.0 mm Hg vs -22.9 mm Hg at 8 weeks; P < 0.0001). After 8 weeks, 71.4% versus 53.8% of patients achieved the BP goal (<140/90 mm Hg) with T/A versus A, with mean SBPs of 131.9 and 137.9 mm Hg, respectively. Similar results were observed in the obese (metabolic syndrome) subpopulation. The more stringent goal (<130/80 mm Hg) was achieved by 36.4% and 17.9% patients in the T/A and A groups, respectively. The most common adverse events were peripheral edema, headache, and dizziness.
CONCLUSIONS: In this selected population of patients with diabetes and hypertension, T/A provided prompt and greater BP decreases compared with A monotherapy, with the majority of patients achieving the BP goal (<140/90 mm Hg).
Arya M Sharma; George Bakris; Joel M Neutel; Thomas W Littlejohn; Maureen Kobe; Naitee Ting; Ludwin Ley
Related Documents :
7116659 - Adrenergic activity in systolic hypertension.
540429 - Catecholamines and haemodynamics in fixed essential hypertension.
22848069 - Excessive wave reflections on admission predict post-discharge events in patients hospi...
8610899 - The effect of a cyclodextrin vehicle on the cardiovascular profile of propofol in rats.
6111139 - The effect of beta blockade on the reaction of pressure and mesenteric flow to biogenic...
24366839 - A prospective cohort study of prognostic factors for the healing of heel pressure ulcers.
14967579 - The effect of posterior tibialis tendon dysfunction on the plantar pressure characteris...
22449049 - The structure of the phloem - still more questions than answers.
22607349 - Left ventricular diastolic dysfunction in newly diagnosed untreated hypertensive patients.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2012-03-03
Journal Detail:
Title:  Clinical therapeutics     Volume:  34     ISSN:  1879-114X     ISO Abbreviation:  Clin Ther     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-03-23     Completed Date:  2012-07-16     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  7706726     Medline TA:  Clin Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  537-51     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier HS Journals, Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amlodipine / administration & dosage*,  adverse effects,  pharmacology,  therapeutic use
Antihypertensive Agents / administration & dosage*,  adverse effects,  pharmacology,  therapeutic use
Benzimidazoles / administration & dosage*,  adverse effects,  pharmacology,  therapeutic use
Benzoates / administration & dosage*,  adverse effects,  pharmacology,  therapeutic use
Blood Pressure / drug effects
Body Mass Index
Diabetes Mellitus, Type 2 / complications,  drug therapy*
Double-Blind Method
Drug Combinations
Hypertension / complications,  diagnosis,  drug therapy*
Middle Aged
Severity of Illness Index
Treatment Outcome
Reg. No./Substance:
0/Antihypertensive Agents; 0/Benzimidazoles; 0/Benzoates; 0/Drug Combinations; 1J444QC288/Amlodipine; U5SYW473RQ/telmisartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A Retrospective Database Analysis of Neuropathic Pain and Oral Antidiabetic Medication Use and Adher...
Next Document:  Hereditary Angioedema Therapies in the United States: Movement Toward an International Treatment Con...